Study Group: Urologic Oncologists (US)(?)
Council Members in this Study Group: 145
Request a survey with this Study Group
Leading Experts in this Study Group
Consultant
Medical Consulting Firm of Dr. Ben Ebrahimi
Ben Ebrahimi, MD, is Director of Clinical Trials at Wilshire Oncology Medical Group. Dr. Ebrahimi oversees clinical trials in various tumor types and treats a variety of cancer patients including lung, breast, colorectal, and lymphomas. These clinical trials include biological agents as well as targeted...
Assistant Professor of Medicine
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Charles Ryan, MD, is an Assistant Professor of Medicine in the Division of Hematology/Oncology at the University of California San Francisco. His clinical research interests in prostate cancer include hormonal therapies, drug development strategies utilizing targeted therapies as well as angiogenesis...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
This is the 4th in its class of oral antiemetics to control acute phase CINV. It is likely to be cost-prohibitive in the company of generical ondansetron. Palonosetron's control of delayed CINV in the IV formulation makes it the better choice among it's class; therefore, losing this indication...
1) This article is a bit confusing as in the beginning it refers to hormone sensitive disease,when in fact,later in the text,it is the HRPC(hormone refracory prostate cancer) cells that are targetted. 2)That being said,the mechanism of action and animal data look interesting and certainly worth pursuing...
Prior studies had suggested an improvement in survival when calcitriol was added to weekly docetaxel. The premature closure of this study ocurred due to an increased death rate in patients receiving the combination of weekly docetaxel compared to q 21 day docetaxel. Faulty trial design, and not necessarily...
Torisel is a prodrug of Rapamune, Wyeth's marketed immunosuppressant product. It is possible that cost concerns could lead to use of Rapamune as a "poor man's substitute" for Torisel.
The Satraplatin trial used an unusual endpoint, and the results may not be as good as they appear at first glance.
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Academic Institution*
- Non-Academic Community Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Physician - Director
- Professor
- Physician - Division Head
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms